Frontiers in Oncology | Thoracic Oncology

Original Research

Accepted on 30 Jan 2026

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for Driver Gene-Negative Advanced NSCLC: A Single-Center Retrospective Real-World Study

in Thoracic Oncology

Lulin Zeng
Yan Xiang
Ao Sun
Kaihua Lu

Frontiers in Oncology

170 views

Original Research

Accepted on 29 Jan 2026

The STAT3–ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer

in Thoracic Oncology

Tzu-Hua Chang
Meng-Feng Tsai
Shang-Gin Wu
Yi-Nan Liu
Huey-Dong Wu
Tzu-Hsiu Tsai
Han-Nian Jheng
Chia-Lang Hsu
Pu Sheng Yeh
Jin-Yuan Shih

Frontiers in Oncology

Case Report

Published on 29 Jan 2026

Furmonertinib plus pemetrexed in the treatment of EGFR exon 19 deletion lung adenocarcinoma: two case reports

in Thoracic Oncology

Yuan Zhang
Duofang Wang
Huaxiu Ma
Xiaojun Wang

Frontiers in Oncology

doi 10.3389/fonc.2026.1709552

546 views

Mini Review

Published on 29 Jan 2026

The chick embryo chorioallantoic membrane as an experimental model to study lung cancer

in Thoracic Oncology

Domenico Ribatti

Frontiers in Oncology

doi 10.3389/fonc.2026.1758487

413 views

Case Report

Published on 29 Jan 2026

Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer

in Thoracic Oncology

Yan Wang
Yan Zhang
Chenlei Cai
Xinyu Liu
Shengxiang Ren
Songwen Zhou

Frontiers in Oncology

doi 10.3389/fonc.2026.1730615

444 views

Editorial

Accepted on 28 Jan 2026

Editorial: Treatment Response and Resistance to Targeted Therapies for NSCLC

in Thoracic Oncology

Shiyou Wei
Zhi Wei
Yu Liu
Yong Zhang
Gao Zhang

Frontiers in Oncology

Systematic Review

Accepted on 28 Jan 2026

ctDNA clearance predicts survival in unresectable EGFR-mutant NSCLC: a meta-analysis

in Thoracic Oncology

Peixian Li
Yujiao Zhang
Fangyuan Qin
Rui Li

Frontiers in Oncology

144 views

Original Research

Published on 28 Jan 2026

Shox2 and Rassf1a DNA methylation: diagnostic utility and association with clinical stage, histological progression and gene mutational landscape in lung adenocarcinoma

in Thoracic Oncology

Yixin Li
Yangli Zhang
Abida Alimu
Yulu Tan
Xiaojie Zhang
Linguo Xiang
Jia Li
Zhangling Liu

Frontiers in Oncology

doi 10.3389/fonc.2026.1727695

360 views

Original Research

Published on 27 Jan 2026

Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations

in Thoracic Oncology

Qiongxia Hu
Jing Wang
Juan Jiang
Zhujun Deng
Kang Xie
Wengeng Zhang
Weimin Li
Bojiang Chen

Frontiers in Oncology

doi 10.3389/fonc.2026.1717191

604 views

Case Report

Published on 27 Jan 2026

Triple-positive non-small cell lung cancer harboring EGFR mutation, ALK rearrangement, and high PD-L1 expression: a case report and literature review

in Thoracic Oncology

Mengjie Mao
Qingxiu Tao
Zhuo Zuo
Jun Ge
Yuke Tian
Bin Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1727899

928 views

Correction

Published on 27 Jan 2026

Correction: Factors associated with longer brain metastasis-free survival in limited-disease small-cell lung cancer who underwent concurrent chemoradiotherapy, a retrospective analysis

in Thoracic Oncology

Xiang-Rong Zhao
Jia Li
Zhen Zhang
Chao Gao
Zheng-Qiang Yang

Frontiers in Oncology

doi 10.3389/fonc.2026.1791673

297 views

Original Research

Published on 27 Jan 2026

Postoperative pulmonary rehabilitation compliance among patients with lung cancer: a cross-sectional survey

in Thoracic Oncology

Xiangting Hu
Fengqiu Sun
Lingyan Jiang

Frontiers in Oncology

doi 10.3389/fonc.2025.1687014

825 views

Original Research

Published on 27 Jan 2026

Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis

in Thoracic Oncology

Sean C. Dougherty
Rishika Singh
Caleb McKinney
Aditya Singh
Jack Masur
Alia C. Lynch
Ryan D. Gentzler
Wendy Novicoff
Nathan Roberts
Richard D. Hall

Frontiers in Oncology

doi 10.3389/fonc.2025.1651192

512 views

Case Report

Accepted on 26 Jan 2026

Case Report: Pembrolizumab Monotherapy Achieves Durable Disease Control in a Patient with BRAF V600E-Mutant Advanced Lung Adenocarcinoma and High PD-L1 Expression Intolerant to BRAF/MEK Inhibition

in Thoracic Oncology

Wei Zhao
rong zhou
Chunlai Feng

Frontiers in Oncology

152 views

Original Research

Published on 26 Jan 2026

CYP4B1 inhibits lung adenocarcinoma progression via PI3K/AKT/mTOR pathway: mechanistic insights and development of a CYP4B1-related prognostic signature

in Thoracic Oncology

Guoyin Li
Jing Kang
Xiaoyan Li
Liping Zhao
Yuhang Chen
Chenlu Gong
Zhiqiang Liu
Bi Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1661650

893 views

Study Protocol

Published on 26 Jan 2026

TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations

in Thoracic Oncology

Thomas Newsom-Davis
Barbara Melosky
Rebecca S. Heist
Shun Lu
Giulia Pasello
Xiwei Chen
Marta Stachowiak
Pavlo Lyfar
Alessandra Forcina
Suresh S. Ramalingam

Frontiers in Oncology

doi 10.3389/fonc.2025.1721624

1,208 views

Original Research

Published on 23 Jan 2026

Safety and efficacy of CT-guided percutaneous microwave ablation for stage I non-small cell lung cancer combined with moderate-to-severe pulmonary dysfunction

in Thoracic Oncology

Yuxian Chen
Chengcheng Du
Chunhai Li
Hong Meng
Fanlei Kong

Frontiers in Oncology

doi 10.3389/fonc.2026.1750853

762 views

Review

Published on 23 Jan 2026

Direct pulmonary delivery route in lung cancer: a highway for siRNA therapeutics

in Thoracic Oncology

Muhammad Shakeeb Sharif
Luca Luzzi
Michelino De Laurentiis
Antonio Giordano
Marcella Barbarino

Frontiers in Oncology

doi 10.3389/fonc.2025.1722906

699 views

Original Research

Published on 23 Jan 2026

Impact of smoking on immune feature and prognosis in unresectable stage III anaplastic lymphoma kinase positive non-small-cell lung cancer

in Thoracic Oncology

Ying Jiang
Zhihui Zhang
Jianzhong Cao
Jianchun Duan
Tao Zhang
Yu Wang
Weihua Li
Fengwei Tan
Jianming Ying
Nan Bi

Frontiers in Oncology

doi 10.3389/fonc.2025.1594479

515 views

Original Research

Published on 22 Jan 2026

Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection

in Thoracic Oncology

Eyad Himdiat
Jean-François Haince
Rashid A. Bux
Guoyu Huang
Paramjit S. Tappia
Bram Ramjiawan
Maria Vaida

Frontiers in Oncology

doi 10.3389/fonc.2025.1718863

619 views

Review

Published on 22 Jan 2026

Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies

in Thoracic Oncology

Mehek Sharma
Anvay Shah
Kimberly A. Rivera-Caraballo
Girindra Raval
Balveen Kaur
Gerald C. Wallace

Frontiers in Oncology

doi 10.3389/fonc.2026.1717432

1,079 views

Original Research

Published on 21 Jan 2026

The modified Glasgow prognostic score serves as a robust predictor of unplanned readmission and 1-year mortality in lung cancer patients receiving immune checkpoint inhibitors

in Thoracic Oncology

Fengwang Xue
Ruoqing Lu
Cailian Wang
Qilian Xiong
Ying Liu
Shengmin Guo
Bo Deng

Frontiers in Oncology

doi 10.3389/fonc.2025.1698848

661 views

Original Research

Accepted on 20 Jan 2026

Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study

in Thoracic Oncology

Giulia Pasello
Claudia Proto
Carlo Genova
Alberto Pavan
Elisa Roca
Gabriele Minuti
Carmine D'Aniello
Raffaele Giusti
Sabrina Mariotti
Francesco Jacopo Romano

Frontiers in Oncology

128 views

Case Report

Published on 20 Jan 2026

Long-term survival in extensive-stage small cell lung cancer: a case report on the integration of interventional bronchoscopy and systemic immunotherapy

in Thoracic Oncology

Ganxiu Deng
Shixuan Yan
Victor Bwembya
Xiaoping Zhu
Zhibing Luo
Changwen Deng

Frontiers in Oncology

doi 10.3389/fonc.2025.1733112

733 views

1,967 articles

articles

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for Driver Gene-Negative Advanced NSCLC: A Single-Center Retrospective Real-World Study

The STAT3–ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer

Furmonertinib plus pemetrexed in the treatment of EGFR exon 19 deletion lung adenocarcinoma: two case reports

The chick embryo chorioallantoic membrane as an experimental model to study lung cancer

Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer

Editorial: Treatment Response and Resistance to Targeted Therapies for NSCLC

ctDNA clearance predicts survival in unresectable EGFR-mutant NSCLC: a meta-analysis

Shox2 and Rassf1a DNA methylation: diagnostic utility and association with clinical stage, histological progression and gene mutational landscape in lung adenocarcinoma

Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations

Triple-positive non-small cell lung cancer harboring EGFR mutation, ALK rearrangement, and high PD-L1 expression: a case report and literature review

Correction: Factors associated with longer brain metastasis-free survival in limited-disease small-cell lung cancer who underwent concurrent chemoradiotherapy, a retrospective analysis

Postoperative pulmonary rehabilitation compliance among patients with lung cancer: a cross-sectional survey

Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis

Case Report: Pembrolizumab Monotherapy Achieves Durable Disease Control in a Patient with BRAF V600E-Mutant Advanced Lung Adenocarcinoma and High PD-L1 Expression Intolerant to BRAF/MEK Inhibition

CYP4B1 inhibits lung adenocarcinoma progression via PI3K/AKT/mTOR pathway: mechanistic insights and development of a CYP4B1-related prognostic signature

TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations

Safety and efficacy of CT-guided percutaneous microwave ablation for stage I non-small cell lung cancer combined with moderate-to-severe pulmonary dysfunction

Direct pulmonary delivery route in lung cancer: a highway for siRNA therapeutics

Impact of smoking on immune feature and prognosis in unresectable stage III anaplastic lymphoma kinase positive non-small-cell lung cancer

Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection

Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies

The modified Glasgow prognostic score serves as a robust predictor of unplanned readmission and 1-year mortality in lung cancer patients receiving immune checkpoint inhibitors

Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study

Long-term survival in extensive-stage small cell lung cancer: a case report on the integration of interventional bronchoscopy and systemic immunotherapy